Loxo Oncology, Inc., a biopharmaceutical company involved in the development of medicines for patients with genetically defined cancers, has entered into a collaboration with Bayer to develop and commercialize larotrectinib and LOXO-195, Loxo Oncology’s franchise of highly selective TRK inhibitors for patients with TRK fusion cancers.    Under the agreement, the companies will share development costs on a 50/50 basis, and Loxo Oncology will receive a $400M upfront payment. They are also ...